NextPoint Therapeutics, Inc.
Riale Gilligan is a Senior Scientist at NextPoint Therapeutics, Inc. since March 2022, having previously held roles as a Scientist within the same organization. Prior experience includes a Graduate Student Co-op at Cocoon Biotech and a Protein Chemistry/CMC Co-op at Surface Oncology, where Riale Gilligan characterized antibody degradation mechanisms and developed clinical bioassay methods. Earlier experience includes a Medical Chemistry Co-op at Wave Life Sciences, focusing on the synthesis of stereopure amidites and conducting various analytical tests. Riale Gilligan holds a Master's degree in Bioengineering from Tufts University and a Bachelor's degree in Chemical Engineering and Physics from Northeastern University.
NextPoint Therapeutics, Inc.
NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells.